Table 2_Subclinical pulmonary embolism in first-line/induction therapy of lung cancer - a remaining clinically relevant adverse event.pdf

There was a predominance of locally advanced and metastatic disease (IB-IIB, n = 22; IIIA-C, n = 123; IVA-B, n = 228). Adenocarcinoma was the predominant histology among NSCLC cases (LUAD, n = 146), followed by squamous cell carcinoma and other NSCLC subtypes combined (n = 115); 112 patients had SCLC.</p><p>PE was detected in 61/373 patients, of whom 58 (95%) had subclinical PE. In NSCLC, body-mass-index (BMI) was independently associated with occurrence of PE (OR = 1.111, p = 0.005), while central tumor localization (OR 5.637, p = 0.028) and vascular infiltration (OR 7.683, p = 0.010) were significantly associated with PE in SCLC.

All patients with PE received anticoagulants according to national and international guidelines and no PE-related deaths occurred.</p>Conclusion<p>This single-center analysis demonstrates a high incidence of subclinical PE in newly diagnosed lung cancer patients and identifies clinical risk factors associated with PE development.</p>